No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO to intensive treatment in contrast to patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Castaño-Bonilla, Tamara, Barragán, Eva, Sargas, Claudia, Sanz, Alejandro, Algarra, Lorenzo, Herrera-Puente, Pilar, García-Boyero, Raimundo, Barrios, Manuel, Martinez-Cuadron, David, Rodriguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Serrano-López, Josefina, Martínez-López, Joaquín, Sayas-Lloris, María José, Olave, María Teresa, Riaza-Grau, Rosalía, Castillo, Teresa Bernal-Del, Larrayoz, María José, Amigo, Raquel, Jiménez-Velasco, Antonio, Sánchez, Joaquín, Ayala, Rosa, Blas, Carlos, Lainez, Daniel, Serrano-López, Juana, Sanz, Miguel A., Alonso-Domínguez, Juan M., Montesinos, Pau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427256/
https://www.ncbi.nlm.nih.gov/pubmed/36051360
http://dx.doi.org/10.1155/2022/3132941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427256/
https://www.ncbi.nlm.nih.gov/pubmed/36051360
http://dx.doi.org/10.1155/2022/3132941

Ejemplares similares